Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00559052
Other study ID # VIO16IP07-01
Secondary ID
Status Completed
Phase Phase 2
First received November 14, 2007
Last updated February 9, 2010
Start date March 2008
Est. completion date February 2009

Study information

Verified date February 2010
Source Axcan Pharma
Contact n/a
Is FDA regulated No
Health authority United States: Food and Drug Administration
Study type Interventional

Clinical Trial Summary

EPI leading to maldigestion is a frequent finding in many diseases of the pancreas, such as chronic pancreatitis (CP). Steatorrhea is the most important digestive manifestation in EPI. The current treatment of EPI includes enzyme supplementation with porcine pancreatic enzyme concentrate, consisting mainly of lipase, amylase and protease. An enzyme preparation able to deliver appropriate enzyme levels to the duodenum instead of the mid gut or distal small bowel, would appear to be clinically efficacious for the treatment of steatorrhea in subjects with CP suffering from EPI.


Description:

Day of screening: Subjects will undergo screening procedures prior to entry into the study.

Day 0: Subjects will be admitted to the facility. Day 1: Subjects will undergo a first perfusion/aspiration procedure. Day 2: Subjects will rest. Day 3: Subjects will undergo a second perfusion/aspiration procedure. Day 4: Subjects will be discharged.


Recruitment information / eligibility

Status Completed
Enrollment 22
Est. completion date February 2009
Est. primary completion date February 2009
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Subjects must have the ability to give informed consent

- Female subjects must use a medically acceptable form of birth control and have a negative pregnancy test upon entering the study and not be breast-feeding

- Subjects must have medical condition compatible with exocrine pancreatic insufficiency

- Subjects must be off therapeutic doses of pancreatic enzyme supplementation prior to study entry day

- Subjects must be on omeprazole at least 5 days prior Day 0.

Exclusion Criteria:

- Subjects with a known hypersensitivity and/or contraindication to VIOKASEĀ®16 or to any non-active component of VIOKASE or to any protein of porcine origin

- Subjects with a known hypersensitivity and/or contraindication to omeprazole or to any non-active component of omeprazole

- Subjects on enzyme therapy, H2-receptor antagonists, anticholinergics, antispasmodics prior to study entry

- Female subjects who are pregnant or lactating

- Subjects with acute pancreatitis or acute exacerbations of chronic pancreatic disease

- Subjects with a history of solid organ transplant or significant bowel resection between esophagus and pancreas

- Subjects who have received an investigational new drug within 30 days prior to entry into the study.

- Subjects with a known coagulopathy

- Subjects with any abnormal liver function test

- Subjects known to have a significant medical and/or mental disease that would compromise the subject's welfare or confound the study results

- Subjects who are not on omeprazole at least 5 days prior Day 0

Study Design

Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Diagnostic


Related Conditions & MeSH terms

  • Exocrine Pancreatic Insufficiency

Intervention

Drug:
VIOKASE 16
The VIOKASE 16 is to be taken as 3 tablets with the perfusion procedure.

Locations

Country Name City State
United States Shands Hospital, University of Florida Gainesville Florida
United States Santhi Swaroop Vege, M.D. Mayo Clinic- Rochester Minnesota

Sponsors (4)

Lead Sponsor Collaborator
Axcan Pharma AAIPharma, City Hospital Laboratory Birmingham, Mayo Clinical Services

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Evaluation of the Intraduodenal Lipase activity following single dose administration of VIOKASE16 tablets in EPI after a liquid meal. 4 months No
Secondary Evaluation of the Intraduodenal protease and amylase activities following administration of VIOKASE16 tablets in EPI after a liquid meal. 4 months Yes
See also
  Status Clinical Trial Phase
Completed NCT02823964 - EASY: Extended Access to Sollpura Over Years Phase 4
Completed NCT02563080 - Pancreatic Exocrine Insufficiency in Acute Pancreatitis
Completed NCT01427725 - Special Investigation of LipaCreon on Long-term Use in Patients With Pancreatic Exocrine Insufficiency
Completed NCT01430234 - Enzyme Suppletion in Exocrine Pancreatic Dysfunction Phase 4
Completed NCT05082051 - Oral CDX-7108 in Healthy Adults and EPI Subjects Phase 1
Completed NCT03236038 - Prevalence of Exocrine Pancreatic Insufficiency in Patients With Decompensated Cirrhosis
Completed NCT02598128 - Safety, Tolerability and Fat Absorption Using Enteral Feeding In-line Enzyme Cartridge (Relizorb) N/A
Completed NCT03407534 - Detection of Exocrine Pancreatic Insufficiency in Patients With Diarrhea and Bloating
Completed NCT00559364 - Safety and Efficacy Study of Viokase® 16 for the Correction of Steatorrhea Phase 3
Completed NCT00408317 - Safety and Efficacy Study of ULTRASE® MT20 in Participants With Cystic Fibrosis (CF) and Exocrine Pancreatic Insufficiency (PI) Phase 3
Recruiting NCT04548778 - BÜHLMANN fPELA in the Diagnosis of Exocrine Pancreatic Insufficiency
Completed NCT00449878 - Liprotamase Efficacy Trial in Patients With Cystic Fibrosis-Related Exocrine Pancreatic Insufficiency Phase 3
Completed NCT00297167 - Study to Evaluate the Safety and Efficacy of EUR-1008 (APT-1008) Pancreatic Enzyme Product in Participants With Cystic Fibrosis and Exocrine Pancreatic Insufficiency Phase 3
Completed NCT00981214 - Study of Pancreatic Enzyme Product in Pediatric Participants With Cystic Fibrosis and Exocrine Pancreatic Insufficiency Phase 3
Recruiting NCT05480241 - Exocrine Pancreatic Insufficiency After Acute Pancreatitis and Pancreatic Enzyme Replacement Therapy N/A
Recruiting NCT05261997 - Endotherapy for Painless Chronic Pancreatitis N/A
Completed NCT02370537 - A Study to Investigate How Common Pancreatic Exocrine Insufficiency (PEI) is in Patients With Type 2 Diabetes and Also to Investigate the Uptake of a Single Dose of EPANOVA® or OMACOR® in Patients With Different Degrees of PEI Phase 2
Recruiting NCT04112836 - Pancreatic Cancer Malnutrition and Pancreatic Exocrine Insufficiency in the Course of Chemotherapy in Unresectable Pancreatic Cancer
Completed NCT06278272 - AI Evaluation of Pancreatic Exocrine Insufficiency in CP Patients
Completed NCT02734810 - SIMPLICITY: Studying Impacts on Malabsorption With Liprotamase in Cystic Fibrosis Phase 3